A Retrospective Multicenter Study to Investigate Dosage, Efficacy, and Safety of Perampanel Given as Monotherapy in Routine Clinical Care in Patients With Epilepsy
Phase of Trial: Phase IV
Latest Information Update: 28 Apr 2017
At a glance
- Drugs Perampanel (Primary)
- Indications Epilepsy
- Focus Therapeutic Use
- Sponsors Eisai Inc
- 28 Apr 2017 Results of exploratory analysis assessing the potential of perampanel as monotherapy using data from two prospective open-label extension studies (NCT00735397 and NCT01161524) and a retrospective study (NCT02736162), presented at the 69th Annual Meeting of the American Academy of Neurology.
- 13 Apr 2017 According to an Eisai Inc media release, results assessing perampanel as monotherapy from studies (307, 235 and 504) will be presented at the American Academy of Neurology (AAN) Annual Meeting.
- 06 Dec 2016 Status changed from not yet recruiting to completed, as per the results published at the 70th Annual Meeting of the American Epilepsy Society.